John Piper, MD
Infectious Disease · Newark, DENPI 1083775654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,026 and has fallen 95.5% since, to $46 in 2024.
Across 64 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$258
- Tetraphase Pharmaceuticals, Inc.$213
- Johnson & Johnson$138
- Merck$117
- AbbVie$104
- Janssen Products, LP$99
- plus $518 from 12 others
What the payments were for
- Food & beverage$1,34493%
- Education$997%
- Gifts$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 11 | $258 |
| Tetraphase Pharmaceuticals, Inc. | 7 | $213 |
| Johnson & Johnson | 8 | $138 |
| Merck | 7 | $117 |
| AbbVie(2 entities) | 6 | $104 |
| Janssen Products, LP | 1 | $99 |
| Melinta Therapeutics, LLC | 4 | $86 |
| Gilead | 4 | $79 |
| Paratek Pharmaceuticals, Inc. | 4 | $78 |
| Theratechnologies Inc. | 3 | $55 |
| Octapharma USA, Inc. | 1 | $54 |
| Insmed, Inc. | 2 | $38 |
| Nabriva Therapeutics, PLC | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $18 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Juluca$108
How this compares
$1,447 in reported general payments places this provider in the 70th percentile of 28 infectious disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefepime Hcl | 11 | $1,940 |
| Potassium Chloride | 27 | $376 |
| Sodium ChlorideSodium Chloride 0.45 % | 27 | $300 |
| Cefazolin Sodium | 11 | $298 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Newark
- Wesley EmmonsNewark$4K
- Maya GuptaNewark$2K
- James LeyNewark$946
- Chad DuffaloNewark$723
- Tresa MascarenhasNewark$584
- Shruti PuriNewark$555
- Kristen FaccioloNewark$365
- Alfred BaconNewark$286
- Angela OatesNewark$218
- Stephanie LeeNewark$120
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.